

Supplementary Information

“Allosteric modulation and direct activation of glycine receptors by a tricyclic sulfonamide”

César O. Lara, Carlos F. Burgos, Katherine Fariña-Oliva, Ana M. Marileo, Victoria P. San Martín, David Flaig, Paul Soto-Ortega, Omayra V. Contreras, Anggelo Sazo, Krishna Gaete-Riquelme, Jeremías Corradi, Carola Muñoz-Montesino, Jorge Fuentealba, Patricio A. Castro, Luis G. Aguayo, Cecilia Bouzat, Gustavo Moraga-Cid*, Gonzalo E. Yévenes*

* To whom correspondence may be addressed:

Dr. Gustavo Moraga-Cid, Department of Physiology, Faculty of Biological Sciences,

University of Concepcion, Chile. gumoraga@udec.cl

Dr. Gonzalo E. Yévenes, Department of Physiology, Faculty of Biological Sciences,

University of Concepcion, Chile. gyevenes@udec.cl



A**B**

Figure S1. Interactions of AM-1488 and AM-3607 with GlyRs composed of $\alpha1$, $\alpha2$ and $\alpha3$ subunits. A. The left panel show the AM-1488 (red) and AM-3607 (blue) binding to homomeric $\alpha3$ GlyRs in the presence of glycine (in purple). The right panels display enhanced views of the predicted binding of AM-1488 (in red) or AM-3607 (in blue) to the sulfonamide binding sites within $\alpha1$, $\alpha2$ and $\alpha3$ GlyRs. The image showing the AM-3607- $\alpha3$ GlyR complex, in the presence of glycine, was reproduced from the previously reported structural information (PDB:5TIN) [8]. **B.**

The left model displays the AM-1488 (red) and AM-3607 (blue) binding to the orthosteric site of homomeric $\alpha 3$ GlyRs. The right panels are zoomed views of the predicted binding of the sulfonamides to the orthosteric sites of $\alpha 1$, $\alpha 2$ and $\alpha 3$ GlyRs. The models were generated from the structural coordinates available ($\alpha 1$, PDB:7TU9; $\alpha 2$, PDB:7KUY and $\alpha 3$, PDB:5CFB).

Supplementary Table 1. Energetic parameters of tricyclic sulfonamide interactions with wild-type and mutated GlyRs

Allosteric site	Docking score			$\Delta G_{\text{binding}}$ (kcal/mol)		
	$\alpha 3$ GlyR	$\alpha 2$ GlyR	$\alpha 1$ GlyR	$\alpha 3$ GlyR	$\alpha 2$ GlyR	$\alpha 1$ GlyR
AM-1488	- 4.318	-4.083	-4.302	-68.21	-65.46	-65.51
AM-3607	-3.059	-3.202	-3.006	-58.92	-51.61	-65.32
Orthosteric site	Docking score			$\Delta G_{\text{binding}}$ (kcal/mol)		
	$\alpha 3$ GlyR	$\alpha 2$ GlyR	$\alpha 1$ GlyR	$\alpha 3$ GlyR	$\alpha 2$ GlyR	$\alpha 1$ GlyR
AM-1488	-4.468	-5.440	-6.138	-59.904	-60.69	-59.703
AM-3607	-4.899	-4.255	-6.173	-62.135	-58.55	-64.701

Docking score					
$\alpha 3$ GlyR	Wild-type	F13A	L14A	R27A	L83A
AM-1488	- 4.318	-3.586	-3.139	-4.515	-3.986
AM-3607	-3.059	-3.123	-2.045	-2.570	-3.111
$\Delta G_{\text{binding}}$ (kcal/mol)					
$\alpha 3$ GlyR	Wild-type	F13A	L14A	R27A	L83A
AM-1488	-68.21	-66.39	-61.91	-67.81	-62.05
AM-3607	-58.92	-65.70	-95.37	-62.35	-63.46

Supplementary Table 2. Allosteric potentiation and putative agonistic activity of wild-type and mutated GlyRs by AM-1488.

AM-1488 direct activation				
	α1GlyR	α2GlyR	α3GlyR	α1βGlyR
10 μ M	20 $\pm$ 9 % (n=6)	0.5 $\pm$ 1 % (n=4)	2 $\pm$ 1 % (n=6)	12 $\pm$ 3 % (n=6)
50 μ M	33 $\pm$ 3 %*** (n=8)	6 $\pm$ 3 % (n=8)	4 $\pm$ 1 % (n=8)	50 $\pm$ 10 % (n=7)
ANOVA followed by Bonferroni post-hoc test; ***: p<0.001, α 1GlyR vs α 2/ α 3 GlyRs.				
α3GlyR allosteric potentiation (0.5 μM AM-1488)				
Wild-type	F13A	L14A	R27A	L83A
240 $\pm$ 34 % (n=11)	59 $\pm$ 5 %** (n=5)	56 $\pm$ 14 %** (n=5)	193 $\pm$ 40% (n=7)	5 $\pm$ 4 %*** (n=6)
ANOVA followed Bonferroni post hoc test, wild-type vs L83A, ***, p<0.001; wild-type vs F13A or L14A, **, p<0.01				
α3GlyR direct activation (100 μM AM-1488)				
Wild-type	F13A	L14A	R27A	L83A
14 $\pm$ 3 % (n=3)	1 $\pm$ 1 %* (n=3)	ND* (n=3)	0.5 $\pm$ 0.3 %* (n=4)	ND* (n=3)
ND, not detected currents. ANOVA followed Bonferroni post hoc test, wild-type vs mutated receptors, p<0.05				